Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 9765

PubMed Links for NLM Catalog (Select 9007735)

1.

Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up†.

Peterson DE, Boers-Doets CB, Bensadoun RJ, Herrstedt J; ESMO Guidelines Committee.

Ann Oncol. 2015 Jul 4. pii: mdv202. [Epub ahead of print] Review. No abstract available.

PMID:
26142468
2.

Final overall survival results from a randomised, Phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).

Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C.

Ann Oncol. 2015 Jul 3. pii: mdv276. [Epub ahead of print]

PMID:
26141208
3.

Survival after Resection of Perihilar Cholangiocarcinoma - Development and External Validation of a Prognostic Nomogram.

Groot Koerkamp B, Wiggers J, Gonen M, Doussot A, Allen P, Besselink M, Blumgart L, Busch O, D'Angelica M, DeMatteo R, Gouma D, Kingham T, van Gulik T, Jarnagin W.

Ann Oncol. 2015 Jun 30. pii: mdv279. [Epub ahead of print]

PMID:
26133967
4.

Planning and Reporting of Quality of Life Outcomes in Cancer Trials.

Schandelmaier S, Conen K, von Elm E, You JJ, Blümle A, Tomonaga Y, Amstutz A, Briel M, Kasenda B; DISCO study group.

Ann Oncol. 2015 Jun 30. pii: mdv283. [Epub ahead of print]

PMID:
26133966
5.

Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis.

Ibrahim MF, Mazzarello S, Shorr R, Vandermeer L, Jacobs C, Hilton J, Hutton B, Clemons M.

Ann Oncol. 2015 Jun 28. pii: mdv284. [Epub ahead of print] Review.

PMID:
26122727
6.

Comparison of EP2006, a Filgrastim Biosimilar, to the Reference: a Phase III, Randomized, Double-Blind Clinical Study in the Prevention of Severe Neutropenia in Patients with Breast Cancer Receiving Myelosuppressive Chemotherapy.

Blackwell K, Semiglazov V, Krasnozhon D, Davidenko I, Nelyubina L, Nakov R, Stiegler G, Singh P, Schwebig A, Kramer S, Harbeck N.

Ann Oncol. 2015 Jun 28. pii: mdv281. [Epub ahead of print]

PMID:
26122726
7.

Phase 1/2 study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.

Naito S, Sakai H, Hashine K, Tomita T, Shinohara N, Fujisawa M, Eto M, Ozono S, Akaza H.

Ann Oncol. 2015 Jun 27. pii: mdv280. [Epub ahead of print]

PMID:
26117830
8.

Serial Blood-Based Analysis of AR-V7 in Men with Advanced Prostate Cancer.

Nakazawa M, Lu C, Chen Y, Paller CJ, Carducci MA, Eisenberger MA, Luo J, Antonarakis ES.

Ann Oncol. 2015 Jun 27. pii: mdv282. [Epub ahead of print]

PMID:
26117829
9.

Association between Information Provision and Decisional Conflict in Cancer Patients.

Sim JA, Shin JS, Park SM, Chang YJ, Shin A, Noh DY, Han W, Yang HK, Lee HJ, Kim YW, Kim YT, Jeong SY, Yoon JH, Kim YJ, Heo DS, Kim TY, Oh DY, Wu HG, Kim HJ, Chie EK, Kang KW, Yun YH.

Ann Oncol. 2015 Jun 26. pii: mdv275. [Epub ahead of print]

PMID:
26116430
10.

Flaws in the trial design of IFCT-0802.

Gyawali B, Shimokata T, Honda K, Ando Y.

Ann Oncol. 2015 Jun 25. pii: mdv273. [Epub ahead of print] No abstract available.

PMID:
26113649
11.

High Anabolic Potential of Essential Amino acid Mixtures in Advanced Non-Small Cell Lung Cancer.

Engelen MP, Safar AM, Bartter T, Koeman F, Deutz NE.

Ann Oncol. 2015 Jun 25. pii: mdv271. [Epub ahead of print]

PMID:
26113648
12.

Does activity of anticancer drugs in advanced cancer always translates in effectivity in early stage high-risk disease?

Schrijvers D.

Ann Oncol. 2015 Jun 25. pii: mdv274. [Epub ahead of print] No abstract available.

PMID:
26113647
13.

Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.

Barault L, Amatu A, Bleeker FE, Moutinho C, Falcomatà C, Fiano V, Cassingena A, Siravegna G, Milione M, Cassoni P, De Braud F, Rudà R, Soffietti R, Venesio T, Bardelli A, Wesseling P, de Witt Hamer P, Pietrantonio F, Siena S, Esteller M, Sartore-Bianchi A, Di Nicolantonio F.

Ann Oncol. 2015 Jun 25. pii: mdv272. [Epub ahead of print]

PMID:
26113646
14.

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.

Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S, Curigliano G, Andre F.

Ann Oncol. 2015 Jul;26(7):1518. doi: 10.1093/annonc/mdv241. No abstract available.

PMID:
26109735
15.

Cetuximab, docetaxel and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicentre, phase II GORTEC study.

Guigay J, Fayette J, Dillies AF, Sire C, Kerger JN, Tennevet I, Machiels JP, Zanetta S, Pointreau Y, Bozec Le Moal L, Henry S, Schilf A, Bourhis J.

Ann Oncol. 2015 Jun 24. pii: mdv268. [Epub ahead of print]

PMID:
26109631
16.

Phase II/III study of second-line chemotherapy comparing irinotecan alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05).

Tanabe K, Fujii M, Nishikawa K, Kunisaki C, Tsuji A, Matsuhashi N, Takagane A, Ohno T, Kawase T, Kochi M, Yoshida K, Kakeji Y, Ichikawa W, Chin K, Terashima M, Takeuchi M, Nakajima T; JACCRO GC-05 study group.

Ann Oncol. 2015 Jun 24. pii: mdv265. [Epub ahead of print]

PMID:
26109630
17.

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.

Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, Lu S, Cheng Y, Han B, Chen L, Huang C, Qin S, Zhu Y, Pan H, Liang H, Li E, Jiang G, How SH, Fernando MC, Zhang Y, Xia F, Zuo Y.

Ann Oncol. 2015 Jun 23. pii: mdv270. [Epub ahead of print]

PMID:
26105600
18.

Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.

Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, Yu L, Ke X, Huang H, Shen Z, Fan Y, Li W, Zhao X, Qi J, Huang H, Zhou D, Ning Z, Lu X.

Ann Oncol. 2015 Jun 23. pii: mdv237. [Epub ahead of print]

PMID:
26105599
19.

Treatment of mCRPC in the AR axis-targeted therapy resistant state.

Chi K, Hotte SJ, Joshua AM, North S, Wyatt AW, Collins LL, Saad F.

Ann Oncol. 2015 Jun 22. pii: mdv267. [Epub ahead of print] Review.

PMID:
26101426
20.

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler L, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA.

Ann Oncol. 2015 Jun 19. pii: mdv264. [Epub ahead of print]

PMID:
26091808
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk